Biolase (BIOL)
(Delayed Data from NSDQ)
$0.18 USD
+0.01 (7.10%)
Updated May 13, 2024 04:00 PM ET
After-Market: $0.17 -0.01 (-6.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BIOL 0.18 +0.01(7.10%)
Will BIOL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BIOL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIOL
Quest Diagnostics' (DGX) Efforts to Reduce Health Inequities
BIOL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BIOL
Biolase: Q1 Earnings Snapshot
BIOLASE, Inc. (BIOL) Q1 2024 Earnings Call Transcript
BIOL Stock Earnings: Biolase Misses EPS, Beats Revenue for Q1 2024
Biolase GAAP EPS of -$0.36 misses by $0.19, revenue of $10.13M beats by $0.13M
Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability